Regulatory Approvals

Israeli Pharma Giant Teva Wins FDA Approval for Monthly Schizophrenia Injection Weltruza

By

Regulatory Approvals — Israeli Pharma Giant Teva Wins FDA Approval for Monthly Schizophrenia Injection Weltruza  Haaretz

Read the original at Regulatory Approvals ↗

Auto-published by the finit.news Events monitor from Regulatory Approvals; summarized by AI and may contain errors — verify against the primary source. October 10, 2026.

By

Related Post

Regulatory Approvals

FDA Approves Pritelivir for Refractory HSV in Immunocompromised Adults

Regulatory Approvals

Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia

Regulatory Approvals

FDA approves Parkinson’s drug based on University of Virgini…

Financial News For All

Mergers & Acquisitions

Nvidia in talks to acquire US ‘open’ model start-up Reflection AI

Mergers & Acquisitions

How Paramount-Warner Bros. Merger Could Impact Sports Broadcasting

Mergers & Acquisitions

Cloudflare acquires Deno to improve its Workers programming model

Labor

Amazon layoffs hit hundreds in retail; Seattle impact unclear